A novel antiviral formulation inhibits a range of enveloped viruses.

Nicola F Fletcher; Luke W Meredith; Emma L Tidswell; Steven R Bryden; Daniel Gonçalves-Carneiro; Yasmin Chaudhry; Claire Shannon-Lowe; Michael A Folan; Daniella A Lefteri; Marieke Pingen; Dalan Bailey; Clive S McKimmie; Alan W Baird

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi. org/10.1101 org/10. /2020 transported across the respiratory epithelium to the lymphatic organs (Muhlebach et al., 2011) . Similarly, SARS-CoV-1 causes an acute interstitial pneumonia and was the causative agent of the 2002 SARS coronavirus epidemic. ViroSAL, therefore, has potential applications as a topical or inhaled therapy to treat epitheliotropic viral infections or those that infect the airway or other mucous membranes. The fact that ViroSAL has applications against a wide range of enveloped viruses is of great interest, and while many antivirals have activity against specific viral families, there are few broad-spectrum antivirals currently available. Therefore, these data provide a rationale for future pre-clinical studies to investigate the antiviral properties of ViroSAL in viral infections of mucous membranes including the airway and skin.